BIO-TECHNE Corp - 8-K Filing
BIO-TECHNE Corp agreed to be acquired by Merck KGaA for $73.00 per share in cash, totaling approximately $2.8 billion based on the company's outstanding shares as of June 25, 2026. The transaction requires shareholder approval and regulatory clearances before closing. (Items: 1.01 Entry into a Material Definitive Agreement, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $TECH